References
- Brown GA. (1970). Infusion thrombophlebitis. Br J Clin Pract 24:197–200
- Cannon JB, Adeyinka Williams N, Papp KJ. (1995). Reduction of pain on intravenous infusion with bile salt formulations for a macrolide antibiotic. Int J Pharm 114:65–74
- Celozzi E, Lotti VJ, Stapley EO, Miller AK. (1980). An animal model for assessing pain-on-injection of antibiotics. J Pharmacol Methods 4:285–9
- Chu SY, Deaton R, Cavanaugh J. (1992). Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother Agents Chemother 36:1147–50
- Comereski CR, Williams PD, Bregman CL, Hottendorf GH. (1986). Pain on injection and muscle irritation: a comparison of animal models for assessing parenteral antibiotics. Fundam Appl Toxicol 6:335–8
- Flood KM, Liu R, Peck KD, Zheng J. (1998). Pain reducing parenteral liposome formulation. CA Patent 2279259
- Gupta PK, Patel JP, Hahn KR. (1994). Evaluation of pain and irritation following local administration of parenteral formulations using the rat paw lick model. J Pharm Sci Technol 48:159–66
- Grazia S, Gerald W. (1968). Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res 9:310–18
- Hecker JF, Fisk GC, Lewis GBH. (1984). Phlebitis and extravasation (“tissuing”) with intravenous infusions. Med J Aust 140:658–60
- Jiang Y, Li F, Luan Y, et al. (2012). Formation of drug/surfactant catanionic vesicles and their application in sustained drug release. Int J Pharm 436:806–14
- Kohno Y, Yoshida H, Suwa T, Suga T. (1989). Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob Agents Chemother 33:751–6
- Langtry HD, Brogden RN. (1997). Clarithromycin – a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drug 53:973–1004
- Lovell MW, Johnson HW, Hui HW, et al. (1994). Less-painful emulsion formulations for intravenous administration of clarithromycin. Int J Pharm 109:45–57
- Lu Y, Wang YJ, Tang X. (2008). Formulation and thermal sterile stability of a less painful intravenous clarithromycin emulsion containing vitamin E. Int J Pharm 346:47–56
- Lu Y, Zhang Y, Yang ZY. (2009). Formulation of an intravenous emulsion loaded with a clarithromycin-phospholipid complex and its pharmacokinetics in rats. Int J Pharm 366:160–9
- Mohammadi G. (2011). Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system. Colloids Surf B Biointerfaces 88:39–44
- Nakagawa Y, Itai S, Yoshida T, Nagai T. (1992). Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem Pharrn Bull 40:725–8
- Qin LH, Leng W. (2007). Formulation and evaluation of less-painful clarithromycin lipid microspheres. Arch Pharm Res 30:1336–43
- Zhao L, Liu J, Zhang L, et al. (2013). Self-assembly properties, aggregation behavior and prospective application for sustained drug delivery of a drug-participating catanionic system. Int J Pharm 452:108–15
- Zimmerm C, Gea E, Roig J, et al. (2002). Comparative tolerability of intravenous erythromycin and clarithromycin in hospitalised patients with community-acquired pneumonia results of a double-blind, randomised, prospective study. Clin Drug Invest 22:393–8
- Zimmermann T, Laufen H, Riedel KD, et al. (2001). Comparative tolerability of intravenous azithromycin, clarithromycin and erythromycin in healthy volunteers results of a double-blind, double-dummy, four-way crossover study. Clin Drug Invest 21:527–36